Richard S Lindahl Emergent Bio Solutions Inc. (EBS) insider trading activity

Richard S Lindahl is EVP, Chief Financial Officer of Emergent BioSolutions Inc.. Currently has a direct ownership of 171,009 shares of EBS, which is worth approximately $1.42 Million. The most recent transaction as insider was on Oct 15, 2024, when has been sold 15,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 171K

9.61% 3M change

1.15% 12M change

Total Value Held $1.42 Million

RICHARD S LINDAHL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 15 2024	BUY Grant, award, or other acquisition	-	15,000 Added 8.06%	171,009 Common Stock
Jun 08 2024	SELL Payment of exercise price or tax liability	$16,917 $6.19 p/Share	2,733 Reduced 1.72%	156,009 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$2,318 $3.39 p/Share	684 Reduced 0.43%	158,742 Common Stock
Feb 29 2024	SELL Payment of exercise price or tax liability	$29,189 $3.23 p/Share	9,037 Reduced 5.36%	159,426 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$1,416 $2.74 p/Share	517 Reduced 0.31%	168,463 Common Stock
Feb 21 2024	SELL Sale (or disposition) back to the issuer	$10,872 $2.71 p/Share	4,012 Reduced 2.32%	168,980 Common Stock
Jun 09 2023	BUY Grant, award, or other acquisition	-	73,847 Added 29.92%	172,992 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	18,462 Added 15.7%	99,145 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$13,296 $12.38 p/Share	1,074 Reduced 5.97%	16,906 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$13,394 $13.71 p/Share	977 Reduced 5.15%	17,980 Common Stock
Feb 23 2023	SELL Payment of exercise price or tax liability	$6,349 $14.3 p/Share	444 Reduced 2.29%	18,957 Common Stock
Feb 08 2023	SELL Payment of exercise price or tax liability	$31,747 $13.25 p/Share	2,396 Reduced 10.99%	19,401 Common Stock
Feb 08 2023	BUY Grant, award, or other acquisition	-	101 Added 0.46%	21,797 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	48,333 Added 35.9%	86,291 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$32,426 $39.64 p/Share	818 Reduced 0.95%	85,473 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$41,748 $42.47 p/Share	983 Reduced 2.52%	37,958 Common Stock
Feb 23 2022	SELL Payment of exercise price or tax liability	$21,791 $42.23 p/Share	516 Reduced 1.31%	38,941 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$97,045 $42.23 p/Share	2,298 Reduced 5.5%	39,457 Common Stock
Feb 22 2022	BUY Grant, award, or other acquisition	-	1,836 Added 4.21%	41,755 Common Stock
Nov 15 2021	BUY Open market or private purchase	$112,380 $37.46 p/Share	3,000 Added 6.99%	39,919 Common Stock
May 08 2021	SELL Payment of exercise price or tax liability	$64,947 $61.62 p/Share	1,054 Reduced 2.78%	36,919 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$79,566 $97.15 p/Share	819 Reduced 2.11%	37,973 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$94,425 $93.49 p/Share	1,010 Reduced 2.54%	38,792 Common Stock
Feb 24 2021	BUY Grant, award, or other acquisition	-	8,023 Added 16.78%	39,802 Common Stock
Feb 09 2021	SELL Payment of exercise price or tax liability	$311,341 $123.45 p/Share	2,522 Reduced 7.35%	31,779 Common Stock

Also insider at

CMPX

Compass Therapeutics, Inc. Healthcare

Director

RSL